Clinical Trial Update: Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 [Phase 2]

View source ↗

Summary

Phase 2 rollover study of AKR-501 in chronic Idiopathic Thrombocytopenic Purpura (ITP); results posted for patients who completed 28 days of treatment in Protoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• AKR-501

Snippet

Sponsor: Eisai Inc. | Conditions: Idiopathic Thrombocytopenic Purpura | Phase 2 | Status: COMPLETED | Results posted: 2018-03-16